IMNN-001

IMNN-001 is a DNA-based immunotherapy designed for the localized treatment of advanced ovarian cancer and related gynecologic malignancies. It consists of an interleukin 12 (IL‑12) plasmid DNA vector encased in a nanoparticle delivery system that enables cell transfection and persistent local secretion of the IL‑12 protein. This approach harnesses the potent immunostimulatory properties of IL‑12 to induce T lymphocyte and natural killer cell proliferation within the tumor microenvironment. The drug is administered intraperitoneally and has been evaluated in combination with standard neoadjuvant and adjuvant chemotherapy regimens (carboplatin plus paclitaxel). Developed using Imunon's proprietary TheraPlas platform technology, IMNN‑001 aims to improve overall survival in patients with newly diagnosed advanced epithelial ovarian cancer by enhancing anticancer immunity while maintaining a favorable safety profile[1][4][5][6][7].

Brand names

IMNN-001IMNN001IMNN 001

Other names

IL-12 gene therapy - ImunonIL12 gene therapy - ImunonIL 12 gene therapy - ImunonIL-12 gene therapy - Expression GeneticsIL12 gene therapy - Expression GeneticsIL 12 gene therapy - Expression GeneticsInterleukin-12 gene therapy - EGENInterleukin12 gene therapy - EGENInterleukin 12 gene therapy - EGENInterleukin-12 gene therapy - ImunonInterleukin12 gene therapy - ImunonInterleukin 12 gene therapy - Imunon